(Q24201081)

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Audit of outcomes in motor neuron disease (MND) patients treated with riluzole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

ALS therapy: targets for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Acute hepatitis after riluzole administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Riluzole-induced acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Therapeutic horizons for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Riluzole-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB3

Effects of riluzole on symptom progression in amyotrophic lateral sclerosis

21 January 2018

1 reference

12 December 2020

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group

1 reference

12 December 2020

[Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS]

1 reference

12 December 2020

Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell?

1 reference

12 December 2020

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

1 reference

12 December 2020

Efficacy of riluzole: who are the patients enrolled in the studies?

1 reference

12 December 2020

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review

1 reference

12 December 2020

Riluzole and ALS therapy

1 reference

12 December 2020

German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS).

1 reference

12 December 2020

Strong suspicion of lung toxicity due to riluzole

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis

1 reference

12 December 2020

An acute, life-threatening, hypersensitivity reaction to riluzole

1 reference

12 December 2020

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

12 December 2020